Data sharing, year 1 - Access to data from industry-sponsored clinical trials

New England Journal of Medicine

Volumn 371, Issue 22, 2014, Pages 2052-2054

  Strom, Brian L ^a   Buyse, Marc ^b,c   Hughes, John ^d   Knoppers, Bartha M ^e  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b HASSELT UNIVERSITY   (Belgium)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^d United Kingdom Clinical Research Network   (United Kingdom)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; CLINICAL TRIAL (TOPIC); COMPUTER SECURITY; DRUG INDUSTRY; DRUG RESPONSE; INFORMATION PROCESSING; PREDICTIVE VALUE; RESEARCH ETHICS; RISK FACTOR; SHORT SURVEY; TREATMENT OUTCOME; CONFLICT OF INTEREST; FINANCIAL MANAGEMENT; HUMAN; INFORMATION DISSEMINATION; STATISTICS AND NUMERICAL DATA;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS; INFORMATION DISSEMINATION; RESEARCH SUPPORT AS TOPIC;

EID: 84915821852     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1411794     Document Type: Article

References (4)

1. Ebrahim S, Sohani ZN, Montoya L, et al. Reanalyses of randomized clinical trial data. JAMA 2014;312:1024-32.
2. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013;369:475-8.
3. Christakis DA, Zimmerman FJ. Rethinking reanalysis. JAMA 2013;310:2499-500.
4. Krumholz HM, Ross JS, Gross CP, et al. A historic moment for open science: the Yale University Open Data Access project and Medtronic. Ann Intern Med 2013;158:910-1.